Biotech Values

[Double_Bagel]

Enoxaparin (generic Lovenox®) sales were down 11% to USD 259 million (down from 284 million last quarter), as a result of an exceptionally strong third quarter in 2010, which included initial pipeline filling. In addition, a second generics company has received FDA approval for enoxaparin and an authorized generic was launched in October.

http://www.novartis.com/downloads/investors/financial-results/quarterly-results/q3-2011-media-release-en.pdf (see pg 16)

Any guesses on what earnings MNTA will have? I am guessing the shorts will drive this down more if there is an earnings miss.